Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results